
Each prolonged-release tablet contains naltrexone hydrochloride 8mg and bupropion hydrochloride 90mg.
Other ingredients include lactose, microcrystalline cellulose, hydroxypropyl cellulose, magnesium stearate and other excipients detailed in the patient information leaflet.
Mysimba 8mg/90mg Prolonged-Release Tablets – 112 Tablets
Pack size: 112 prolonged-release tablets
Manufacturer: Orexigen Therapeutics Ireland Limited
Prescription required
Mysimba is a prescription-only medicine containing naltrexone hydrochloride and bupropion hydrochloride.
It is licensed for weight management in adults with an initial BMI of 30 or above, or a BMI of 27 or above with at least one weight-related health condition, alongside a reduced-calorie diet and increased physical activity.
Treatment is subject to an individual clinical assessment by an authorised prescriber. Continued treatment requires monitoring of effectiveness, safety and tolerability.
Each prolonged-release tablet contains naltrexone hydrochloride 8mg and bupropion hydrochloride 90mg.
Other ingredients include lactose, microcrystalline cellulose, hydroxypropyl cellulose, magnesium stearate and other excipients detailed in the patient information leaflet.